Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab

Kristoffer Staal Rohrberg; Helle Pappot; Ulrik Lassen; Maj Westman; René K Olesen; Per Pfeiffer; Morten Ladekarl; Paul Morten Mau-Sørensen; Ib J Christensen; Birgit G Skov

Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab

Kristoffer Staal Rohrberg, Helle Pappot, Ulrik Lassen, Maj Westman, René K Olesen, Per Pfeiffer, Morten Ladekarl, Paul Morten Mau-Sørensen, Ib J Christensen, Birgit G Skov

Teaching

6 Citations (Scopus)

Abstract

Malignancies in the upper gastrointestinal (UGI) tract are amongst the most aggressive cancers and only few treatment options exist. We have recently analyzed data from a phase II trial where patients with UGI cancers were treated with erlotinib and bevacizumab.The combination therapy could not be recommended in an unselected population of patients with chemo-refractory UGI cancer. However, a subpopulation of patients did benefit from the therapy. In this prospectively planned biomarker study we investigated vascular endothelial growth factor A (VEGF-A), VEGF receptor 2 (VEGFR-2) and epidermal growth factor receptor (EGFR) by immunohistochemistry and KRAS mutation status detected by PCR as potential predictors of effect of therapy. High VEGF-A expression was correlated to longer overall survival (HR: 0.8, 95% CI: 0.7-0.9) and high VEGFR-2 expression to shorter progression free survival (HR: 1.4, 95% CI: 1.0-1.9). EGFR expression and KRAS mutation status were not correlated to response or survival. We conclude that VEGF-A and VEGFR-2 could potentially be predictive markers in patients with UGI cancers treated with erlotinib and bevacizumab.

Original language	English
Journal	Cancer Biology & Therapy
Volume	11
Issue number	8
Pages (from-to)	732-9
Number of pages	8
ISSN	1538-4047
Publication status	Published - 15 Apr 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

http://www.landesbioscience.com/journals/cbt/article/14889/

Cite this

Rohrberg, K. S., Pappot, H., Lassen, U., Westman, M., Olesen, R. K., Pfeiffer, P., Ladekarl, M., Mau-Sørensen, P. M., Christensen, I. J., & Skov, B. G. (2011). Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab. Cancer Biology & Therapy, 11(8), 732-9. http://www.landesbioscience.com/journals/cbt/article/14889/

@article{567546ca2006480e8b859f78bb29eae5,

title = "Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab",

abstract = "Malignancies in the upper gastrointestinal (UGI) tract are amongst the most aggressive cancers and only few treatment options exist. We have recently analyzed data from a phase II trial where patients with UGI cancers were treated with erlotinib and bevacizumab.The combination therapy could not be recommended in an unselected population of patients with chemo-refractory UGI cancer. However, a subpopulation of patients did benefit from the therapy. In this prospectively planned biomarker study we investigated vascular endothelial growth factor A (VEGF-A), VEGF receptor 2 (VEGFR-2) and epidermal growth factor receptor (EGFR) by immunohistochemistry and KRAS mutation status detected by PCR as potential predictors of effect of therapy. High VEGF-A expression was correlated to longer overall survival (HR: 0.8, 95% CI: 0.7-0.9) and high VEGFR-2 expression to shorter progression free survival (HR: 1.4, 95% CI: 1.0-1.9). EGFR expression and KRAS mutation status were not correlated to response or survival. We conclude that VEGF-A and VEGFR-2 could potentially be predictive markers in patients with UGI cancers treated with erlotinib and bevacizumab.",

author = "Rohrberg, {Kristoffer Staal} and Helle Pappot and Ulrik Lassen and Maj Westman and Olesen, {Ren{\'e} K} and Per Pfeiffer and Morten Ladekarl and Mau-S{\o}rensen, {Paul Morten} and Christensen, {Ib J} and Skov, {Birgit G}",

year = "2011",

month = apr,

day = "15",

language = "English",

volume = "11",

pages = "732--9",

journal = "Cancer Biology & Therapy",

issn = "1538-4047",

publisher = "Taylor & Francis",

number = "8",

}

TY - JOUR

T1 - Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab

AU - Rohrberg, Kristoffer Staal

AU - Pappot, Helle

AU - Lassen, Ulrik

AU - Westman, Maj

AU - Olesen, René K

AU - Pfeiffer, Per

AU - Ladekarl, Morten

AU - Mau-Sørensen, Paul Morten

AU - Christensen, Ib J

AU - Skov, Birgit G

PY - 2011/4/15

Y1 - 2011/4/15

N2 - Malignancies in the upper gastrointestinal (UGI) tract are amongst the most aggressive cancers and only few treatment options exist. We have recently analyzed data from a phase II trial where patients with UGI cancers were treated with erlotinib and bevacizumab.The combination therapy could not be recommended in an unselected population of patients with chemo-refractory UGI cancer. However, a subpopulation of patients did benefit from the therapy. In this prospectively planned biomarker study we investigated vascular endothelial growth factor A (VEGF-A), VEGF receptor 2 (VEGFR-2) and epidermal growth factor receptor (EGFR) by immunohistochemistry and KRAS mutation status detected by PCR as potential predictors of effect of therapy. High VEGF-A expression was correlated to longer overall survival (HR: 0.8, 95% CI: 0.7-0.9) and high VEGFR-2 expression to shorter progression free survival (HR: 1.4, 95% CI: 1.0-1.9). EGFR expression and KRAS mutation status were not correlated to response or survival. We conclude that VEGF-A and VEGFR-2 could potentially be predictive markers in patients with UGI cancers treated with erlotinib and bevacizumab.

AB - Malignancies in the upper gastrointestinal (UGI) tract are amongst the most aggressive cancers and only few treatment options exist. We have recently analyzed data from a phase II trial where patients with UGI cancers were treated with erlotinib and bevacizumab.The combination therapy could not be recommended in an unselected population of patients with chemo-refractory UGI cancer. However, a subpopulation of patients did benefit from the therapy. In this prospectively planned biomarker study we investigated vascular endothelial growth factor A (VEGF-A), VEGF receptor 2 (VEGFR-2) and epidermal growth factor receptor (EGFR) by immunohistochemistry and KRAS mutation status detected by PCR as potential predictors of effect of therapy. High VEGF-A expression was correlated to longer overall survival (HR: 0.8, 95% CI: 0.7-0.9) and high VEGFR-2 expression to shorter progression free survival (HR: 1.4, 95% CI: 1.0-1.9). EGFR expression and KRAS mutation status were not correlated to response or survival. We conclude that VEGF-A and VEGFR-2 could potentially be predictive markers in patients with UGI cancers treated with erlotinib and bevacizumab.

M3 - Journal article

SN - 1538-4047

VL - 11

SP - 732

EP - 739

JO - Cancer Biology & Therapy

JF - Cancer Biology & Therapy

IS - 8

ER -

Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this